Home » Bavarian Nordic Discusses Smallpox Vaccine Results
Bavarian Nordic Discusses Smallpox Vaccine Results
Denmark’s Bavarian Nordic has completed a placebo-controlled Phase II trial in 745 healthy subjects who received one or two doses of Imvamune, a third-generation smallpox vaccine.
The study, together with other Phase II studies of the drug in immune-compromised people, will help the company obtain an emergency use authorization (EUA).
The company said it expects to receive approval of the EUA in the second half of 2008.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May